Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622372 | 0.87 | FGFR1 (0.69) | FGFR1FLT1HRH4CHEK2DRD3 | |
| SCHEMBL1621942 | 0.87 | ITK (0.44) | FGFR1FLT1HRH4DRD3ACHE | |
| SCHEMBL13869874 | 0.85 | FGFR1 (0.58) | FGFR1FLT1HRH4CHEK2DRD3 | |
| SCHEMBL1622953 | 0.85 | LCK (0.41) | FGFR1FLT1HRH4ACHEHRH3 | |
| SCHEMBL13869880 | 0.83 | FGFR1 (0.61) | FGFR1FLT1HRH4CHEK2DRD3 | |
| SCHEMBL1623222 | 0.77 | ITK (0.45) | FGFR1FLT1DRD3HRH3 | |
| SCHEMBL1622691 | 0.75 | HRH3 (0.43) | FGFR1FLT1HRH4HRH3 | |
| SCHEMBL1621731 | 0.73 | LCK (0.48) | FGFR1FLT1DRD3HRH3 | |
| SCHEMBL1621737 | 0.72 | HRH3 (0.51) | FGFR1FLT1DRD3HRH3 | |
| SCHEMBL1622655 | 0.72 | KDR (0.47) | FGFR1FLT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | FGFR1 846/4885FLT1 1207/4885HRH4 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.